Evotec background for investors, shares in a complex biotech model

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-28, 14:25.

Evotec SE (DE0005664809) is a German biotech company headquartered in Hamburg that focuses on drug discovery alliances and proprietary research programs in multiple therapeutic areas, including neurology, oncology and metabolic diseases.Company profile on Evotec Evotec stock is listed on Xetra, giving investors access to a diversified portfolio of collaborative projects with large pharmaceutical partners such as Bayer and Bristol Myers Squibb.Boerse Frankfurt listing overview

Biotech collaboration model explained

Evotec pursues a collaboration-driven business model, generating revenues from research fees, milestone payments and potential royalties across a range of partnerships with global pharma groups.Evotec investor news and alliances The company operates integrated platforms that span target discovery, hit identification, lead optimization and early preclinical development, aiming to increase productivity for its partners while building a share in future product success.

Its alliances include multi-year arrangements in areas such as metabolic diseases with Bayer and neuroscience programs with Bristol Myers Squibb, where Evotec contributes discovery capabilities and shares in downstream economics.Description of the Bayer metabolic alliance This setup aims to balance nearer-term service revenues with longer-dated upside from clinical and commercial milestones as partnered candidates advance.

Research pipeline and proprietary assets

Beyond fee-for-service work, Evotec invests in a proprietary pipeline, particularly in neurology and metabolic diseases, often co-owned with partners or financed via spin-outs and joint ventures.Evotec pipeline overview The company highlights programs such as its beta cell replacement therapies for diabetes and neurodegeneration projects that aim to modify disease progression rather than only treating symptoms.

Evotec also creates and holds stakes in separate entities, like the diabetes-focused joint venture with Sanofi that formed the basis for its Lyon site, integrating large-scale biochemical screening with translational research capabilities.Press release on the Sanofi diabetes alliance These structures diversify funding sources and allow Evotec to expand its scientific footprint without bearing all clinical risk on its own balance sheet.

What Evotec sells in practice

Evotec does not commercialize many end-user medicines itself but sells discovery and development services, technology platforms and co-owned drug candidates to pharmaceutical companies, alongside contributions to spin-outs that focus clinical development on specific therapeutic areas.

Where the stock trades today

Evotec shares trade on Xetra, with the last verified price published on Boerse Frankfurt at 19.50 euros as of 2026-06-27, 17:45, providing a reference level for investors following the biotech sector.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.